Aphea.Bio’s recent Series C funding round was led by Innovation Industries, with participation from Korys Investments and support from the Bill & Melinda Gates Foundation, SFPIM, BNP Paribas Fortis, as well as returning investors ECBF, Astanor, AIF, and other existing shareholders. It is currently the largest capital round of a growth company in Flanders in 2023.

Of particular significance is Aphea.Bio’s partnership with the Bill & Melinda Gates Foundation, which will focus on developing biostimulant products tailored to the unique needs of smallholder farmers in Sub-Saharan Africa and South Asia, regions that the foundation prioritizes for agricultural support.

This latest funding round coincides with a period of exceptional growth for Aphea.Bio. The company’s team has grown to include over 50 scientists and industry specialists, and they are expanding their research facilities with a new pilot plant. Additionally, Aphea.Bio has achieved the prestigious Certified B Corporation™ status, acknowledging its commitment to high social and environmental impact standards.

Furthermore, the company has made significant strides in its product portfolio. The recent successful launch of ΛCTIV by Aphea.Bio®, a groundbreaking biostimulant seed treatment, marked Aphea.Bio’s entry into the market. Looking forward, the company is actively preparing for the launch of its very first maize biostimulant in 2024 and plans to submit its first biofungicide for regulatory approval in the US and Europe in the first and third quarters of 2024, respectively.